Natera, Inc.(Italy) and Quest Diagnostics Incorporated (US) are Leading Players in the Carrier Screening Market
The global Carrier Screening Market is expected to reach USD 5.4 billion by 2028 from USD 2.2 billion in 2023, at a CAGR of 19.7% during the forecast period. The growth of this market is majorly driven by Increasing emphasis on early disease detection and prevention. However, Lack of skilled professionals is one of the challenges for which may obstruct the growth of this market.
The key players operating in this market are Invitae Corporation. (US) , Fulgent Genetics. (US), Eurofins Scientific (Germany), OPKO Health, Inc.(US), Thermo Fisher Scientific Inc.(US), Quest Diagnostics Incorporated (US), Myriad Genetics, Inc. (US), Illumina, Inc.(US), Natera, Inc.(Italy), Laboratory Corporation of America Holdings. (US), CENTOGENE N.V.(Germany), and DiaSorin S.p.A.(Italy)
To know about the assumptions considered for the study download the pdf brochure
Natera, Inc.
Natera, Inc. is a diagnostics and genetic testing company engaged in the development and commercialization of non-invasive methods for the analysis of DNA samples. It is a global leader in cell-free DNA (cfDNA) testing, in the field of oncology, women’s health, and organ health. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. The company majorly operates through two segments, Product Revenue and Licensing & Other Revenues. Carrier screening testing services are provided through its Product Revenue segment.
The company’s portfolio includes genetic tests, Horizon (Advanced Carrier screening), Panorama (non-invasive prenatal test), Vistra (a complement to Panorama), Horizon Carrier Screening test (HCS), Spectrum PGS (preimplantation genetic screening), Spectrum PGD (pre-implantation genetic diagnosis), Anora Products of Conception (POC) test, and Non-invasive Paternity Testing (PAT).
Natera has a direct sales force in the US and a global network of ~100 laboratories and distribution partners, inclusive of the largest international laboratories across the world. In 2022 the company spent USD 96.09 million on its R&D. The company may have established collaborations and partnerships with healthcare providers, research institutions, and pharmaceutical companies to advance its genetic testing capabilities and expand its market reach.
Quest Diagnostics Incorporated
Quest Diagnostics provides diagnostic information services and operates through two business segments, namely, Diagnostic Information Services (DIS) and Diagnostic Solutions. Through its DIS segment, the company offers testing solutions, including services for the predisposition, diagnosis, treatment, and monitoring of cancers & other diseases. The DIS segment also offers tests in various fields, including endocrinology, immunology, infectious diseases, neurology, oncology, and cardiology.
Quest Diagnostics provides carrier screening panels, covering a broad range of genetic disorders through its physician hospital and laboratory services under the DIS business segment. Quest has a nationwide network of laboratories, patient service centers, and physician’s office laboratories in the US.
Fulgent Genetics.
Fulgent Genetics is a genetic testing company that provides comprehensive genetic testing solutions for various applications, including medical genetics, reproductive health, and cancer genetics. The company aims to offer flexible and customizable genetic testing services to healthcare providers and organizations.
The company offers the catalog of genetic testing, including over 18,000+ single gene tests, 900+ rare disease tests, whole genome sequencing, whole genome copies number variation analysis, mitochondrial sequencing, and CLIA/CAP quality sequencing services and operates 7 labs across the United States. Fulgent Genetics has a strong presence in the US.
Related Reports:
Carrier Screening Market by Product and Service, Type (Expanded (Customized, Predesigned) Targeted Diseases, Medical condition (Hematologic, Pulmonary), Technology (DNA Sequencing, PCR), End user, Region - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
